Merck KGaA has raised its full-year earnings outlook for the third time this year, driven by robust performance in its life science division and a slower-than-anticipated decline in sales of its multiple sclerosis drug Mavenclad.
The company now expects adjusted earnings to range between €6.2 billion and €6.4 billion ($7.1 billion), up from its previous upper-end forecast of €6.3 billion. Merck KGaA also increased its net sales guidance for the year, reflecting continued strength in its lab-equipment business.
The latest revision underscores the company's resilience in a challenging market environment, as it navigates the gradual decline of Mavenclad while expanding its footprint in high-growth areas like lab equipment.